Ernest Marshall

TL;DR: In this paper, the authors compared pembrolizumab versus placebo in patients with resected high-risk stage III melanoma, and showed that penglizumaab adjuvant therapy provided a significant and clinically meaningful improvement in distant metastasis-free survival at a 3·5-year median followup.

TL;DR: A multicentre, open-label, randomised controlled phase 3 trial to assess the role of bevacizumab as adjuvant treatment for patients with resected melanoma at high risk of recurrence, with promising tolerability.

TL;DR: This study, using the combination of dacarbazine and treosulfan, while well tolerated, did not confirm earlier reports suggesting treOSulfan is active in uveal melanoma.

TL;DR: High-dose suramin was associated with higher objective and PSA response rates, but these were not statistically significant, and the lack of a dose-response relationship and the toxicity profile observed raise questions regarding the utility of suramin, particularly high-doseSuramin, as administered on this schedule.

TL;DR: In this paper, a pilot study sought to provide an early indication of whether the same effects can be achieved with the intravenous component of HDI alone and inform the feasibility and design of a phase III trial.